T-cell Lymphoma Clinical Trials

11 recruiting

T-cell Lymphoma Trials at a Glance

56 actively recruiting trials for t-cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 2 with 29 trials, with the heaviest enrollment activity in New York, Houston, and Boston. Lead sponsors running t-cell lymphoma studies include Fudan University, Memorial Sloan Kettering Cancer Center, and Ruijin Hospital.

Browse t-cell lymphoma trials by phase

Treatments under study

About T-cell Lymphoma Clinical Trials

Looking for clinical trials for T-cell Lymphoma? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new T-cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about T-cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 56 trials

Recruiting
Phase 2

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
St. Jude Children's Research Hospital100 enrolled3 locationsNCT06390319
Recruiting
Phase 1

CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory T-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University25 enrolled1 locationNCT06696846
Recruiting
Phase 2

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Lymphoproliferative DisordersImmune System DiseasesPeripheral T-cell Lymphomas
National Cancer Institute (NCI)330 enrolled2 locationsNCT03922724
Recruiting
Phase 1

CD4CAR for CD4+ Leukemia and Lymphoma

T-cell LymphomaT-cell Leukemia
Huda Salman20 enrolled6 locationsNCT03829540
Recruiting
Phase 1Phase 2

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)

T-cell Lymphomas
Dizal Pharmaceuticals165 enrolled12 locationsNCT07496229
Recruiting
Phase 1Phase 2

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

Hodgkin LymphomaNon-Hodgkin LymphomaLymphoma+4 more
AstraZeneca161 enrolled33 locationsNCT06137144
Recruiting
Phase 1Phase 2

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

LGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell LymphomaPrimary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma+2 more
Dren Bio200 enrolled37 locationsNCT05475925
Recruiting
Phase 2

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

T-cell Lymphoma
Jonathan Brammer44 enrolled1 locationNCT07356245
Recruiting
Phase 2

Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Sun Yat-sen University84 enrolled1 locationNCT06583083
Recruiting
Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 1

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

T-cell Prolymphocytic LeukemiaT-cell LymphomasNK-Cell Lymphomas+1 more
Memorial Sloan Kettering Cancer Center70 enrolled9 locationsNCT05010005
Recruiting
Phase 2

A Study of Enasidenib in People With T-Cell Lymphoma

T-cell Lymphoma
Memorial Sloan Kettering Cancer Center25 enrolled8 locationsNCT06756308
Recruiting
Phase 2

Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Fudan University210 enrolled7 locationsNCT06314334
Recruiting
Phase 3

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Lymphoma, T-CellPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc.150 enrolled34 locationsNCT06561048
Recruiting
Phase 3

Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma

Maintenance Treatment of Peripheral T-cell Lymphoma
Fudan University136 enrolled1 locationNCT07300514
Recruiting
Phase 2

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL

Natural Killer/T-cell Lymphoma
Ruijin Hospital47 enrolled1 locationNCT07380984
Recruiting
Phase 1

Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

Refractory/Recurrent Peripheral T-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University45 enrolled1 locationNCT07164560
Recruiting
Phase 1

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

T-cell Acute Lymphoblastic LeukemiaLymphoblastic T-Cell Lymphoma
OneChain Immunotherapeutics20 enrolled2 locationsNCT05679895
Recruiting
Phase 1Phase 2

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Ovarian CancerMelanomaT-cell Lymphoma+1 more
BioInvent International AB176 enrolled25 locationsNCT04752826
Recruiting
Phase 1

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.255 enrolled17 locationsNCT06393738